Re: PZ) Novartis Delivers Strong Start to 2006 ......and what of the pat

[Guest guest]

> >Sounds like they are doing very well out of us! Any chance of a

> >reduction of the cost-to-patient do you think?

>

>

> Hopefully, having new drug choices offered by different drug

companies will

> eventually make a difference in the cost of these drugs. It will be

> interesting to see what Bristol-Myers Squibb charges for BMS when it is

> approved, most likely soon. If they want to steal some patients away

from

> Norvartis and Gleevec, they would price it lower than Gleevec! When

Gleevec

> was priced, there was no competition.......it was priced same as the

usual

> dose of interferon, and there was no comparison on tolerance and side

> effects, and response........so Novartis won the market. And there

are more

> drugs in the pipeline.....so maybe some day we will see some price

> competition.

>

>

>

__________________________________________________________

It's an interesting issue, Nanc. My guess is that dasatinib or Sprycel

will be priced about the same as Gleevec,or perhaps a little higher,

and the price of Gleevec may decline somewhat. What is an even more

interesting question is whether the price structure of Gleevec and

Sprycell will change once AMN-107 is on the market.